晚期无症状滤泡性淋巴瘤立即治疗或观察等待并延迟化疗的成本效益
该分析从英国国家卫生服务体系视角,用马尔可夫决策模型比较晚期无症状滤泡性淋巴瘤立即治疗与观察等待的成本效益。结果显示,与观察等待相比,两种利妥昔单抗策略均更有效且节省成本;与利妥昔单抗诱导相比,加利妥昔单抗维持仅轻微增加有效性但大幅增加成本,ICER为每质量调整生命年69406英镑。概率敏感性分析中,在每QALY 20000英镑阈值下,利妥昔单抗诱导具有68%的成本效益概率。
要点
- 与观察等待相比,利妥昔单抗诱导联合或不联合维持治疗均更有效且节省成本。
- 与利妥昔单抗诱导相比,加用利妥昔单抗维持的ICER为每QALY 69406英镑。
- 在每QALY 20000英镑阈值下,利妥昔单抗诱导具有68%的成本效益概率。
核心结论
- 作者认为,对无症状滤泡性淋巴瘤患者,采用利妥昔单抗诱导的积极治疗是具有成本效益的策略。
研究设计与样本
- 开发马尔可夫决策模型,从英国国家卫生服务体系视角估算无症状滤泡性淋巴瘤患者治疗策略的成本效益。
- 模型有效性数据来自系统性文献综述,关键临床数据来源于一项比较治疗策略的随机试验;成本采用英国国家来源估算。
主要发现
- 与观察等待相比,两种利妥昔单抗策略均更有效且节省成本。
- 与利妥昔单抗诱导相比,加利妥昔单抗维持仅轻微增加有效性但大幅增加成本,ICER为每QALY 69406英镑。
- 概率敏感性分析中,在每QALY 20000英镑阈值下,利妥昔单抗诱导具有68%的成本效益概率。
临床怎么用
- 原文结论认为,对无症状滤泡性淋巴瘤患者,采用利妥昔单抗诱导的积极治疗是具有成本效益的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent evidence has shown that immediate treatment with rituximab induction, with and without maintenance, substantially reduces the need for further treatment in patients with advanced asymptomatic follicular lymphoma. This analysis estimates the cost-effectiveness of immediate treatment approaches in comparison to a watch and wait approach from the perspective of the UK National Health Service. A Markov decision model was developed to estimate the cost-effectiveness of treatment strategies in patients with asymptomatic follicular lymphoma. The model was populated using effectiveness data from a systematic literature review with the key clinical data sourced from a randomised trial, in which the treatment strategies were compared. Costs were estimated using UK national sources. In comparison to watchful waiting, both rituximab strategies were found to be more effective and cost saving. In comparison to rituximab induction, the addition of rituximab maintenance marginally increased effectiveness but substantially increased costs, resulting in an incremental cost-effectiveness ratio (ICER) of £69 406 per quality-adjusted life year (QALY). In probabilistic sensitivity analysis, rituximab induction was found to have a 68% probability of being cost-effective at a threshold of £20 000 per QALY. In conclusion, active treatment with rituximab induction is a cost-effective strategy to adopt in patients with asymptomatic follicular lymphoma.
引用
- Prettyjohns M, Hoskin P, McNamara C, et al. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. Br J Haematol. 2017. PMID: 29076139. doi:10.1111/bjh.14990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。